Scooby Blue...where are you? Well, no problems, only solutions, actually disolutions, dellusions and/or desillusions.
Raptiva was supposed to be selling 10 times Embrel for psoriasis by now ($400 millions first year, $1 billion by year 2004) and it is doing barely $40 millions for first year.
Raptiva side effects profile was supposed to be like plain drinking water and end up being onerous at best, they did not pain attention to BLEEDING as a side effect.
Raptiva was supposed to be the wonder drug of transplantation, and it is good for not.
Raptiva was going to kick in RA and it was kicked off from RA market, actually it INCREASES arthritis.
Besides that, whatever money is made on it, goes to DNA, and any leftover to Mlnm dust bin drugs (oned DOA, the other on the way to RIP).
Royalties were...well it is not PDLI !!!
The rest of the technology was bluffing.
And Bpi was the everhope...neveready, the superpipeline, actually pipedream that could...but was finally kill with the unending misses, the constantly archived phase IIs, unevolving phase IIs and disastrously expensive wreckages IIIs.
But, going into acne was too much even for b(ur)pi(ng)eye, why acne if even the least ready retina drug company commands a market value ahead of xoma!, the market seems to realize that going fast and furiously into acne means no hope in retina (besides the long list of bpi had beens).
Well, no fuel, the pre-drop under $3 was as usual predictive of bad news, only to go with the general market mood and come back down worse than the slow dying.
xoma has recovered multiple times, but now seems to be only the carcass left, will PDLI has mercy? Serono? or Chiron? DNA? who will pick the drying bones? |
